Biotech Summit 2021 – Panel Discussion & Exclusive Genentech Tour | Virtual Event
The program begins with a discussion on the science and application of biomarker testing, how biomarkers have advanced treatment for so many patients and the critical need to make testing more accessible and ultimately drive improved patient outcomes and health care equity for Oregonians and Washingtonians.
Tzvia Bader, CEO and Co-founder of TrialJectory
Ms. Bader is pushing the pharmaceutical industry to rethink their approach to oncology research. Her mission isn’t fueled by ‘buzzwords’ or hypothetical scenarios, but the endless roadblocks and lack of information that she and her mother faced trying to navigate their own cancer journeys.
Dr. Chris Corless, M.D., Ph.D, Executive Director and Chief Medical Officer, Knight Diagnostic Laboratories and Professor of Pathology, OHSU
After undergraduate studies at the Univ. of California, Berkeley, Dr. Corless received his MD and PhD degrees from Washington University, St. Louis. He did his residency training in Anatomic Pathology at the Brigham & Women’s Hospital, Boston, where he also completed fellowship training in GI Pathology and GU Pathology. He joined the faculty of Oregon Health & Science University in 1994 and was promoted to Professor in 2004. During his career he has served as the residency program director in Pathology and medical director of surgical pathology for OHSU Hospital. He is presently the Director of the Knight Diagnostic Laboratories and the Knight Biolibrary at OHSU. An author on over 280 publications, Dr. Corless has expertise in the application of molecular diagnostics to the classification and prognostication of solid tumors.
Dr. Rachel Sanborn, M.D., Medical Director, Thoracic Oncology Program and Phase I Clinical Trials Program, Earle A. Chiles Research Inst., Providence Cancer Institute
As director of the Phase I Clinical Trials Program at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in Portland, Ore., Dr. Sanborn leads one of the largest portfolios of early-phase cancer clinical trials on the West Coast. As a board-certified medical oncologist and co-director of the Providence Thoracic Oncology Program, she is an active investigator of numerous studies of immunotherapies, targeted therapies, and combination therapies for patients with lung cancer. She is a member of several groups, including the American Society of Clinical Oncology, the Society for Immunotherapy of Cancer, the International Association for the Study of Lung Cancer, and the Lung Cancer Research Foundation, and she is co-chair of the Hoosier Cancer Research Network Thoracic Clinical Trial Working Group.
JB Smith, Genentech BioMarker Account Executive, will moderate the discussion.
Following the panelist session, a virtual tour takes participants on an exclusive virtual behind-the-scenes tour of Genentech’s new 130,000-square-foot Hillsboro Individualized Therapies (HIT) facility, a $175-million state-of-the-art new manufacturing facility for individualized therapies located in Hillsboro, Oregon.
Presenting Sponsors: Genentech ● Biogen ●BIO ●PhRMA
Supporting Sponsors: Absci ● Biotronik ● CAI ● Micro Systems Engineering ● Twist Bioscience ● VWR
